FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
FDA advisors unanimously voted to back Moderna's mRNA-1010 flu vaccine, which showed 27% higher efficacy than standard shots, while the agency navigates political drama and a pending CDC review.